









Markets
/
Stocks
/
nasdaq-fdmt
/

4D Molecular Therapeutics Inc

FDMT



View Detailed Chart

10.500USD

-0.420-3.85%

Close 11/07, 16:00（ET）Quotes delayed by 15 min

490.35MMarket Cap

LossP/E TTM



4D Molecular Therapeutics Inc

10.500

-0.420-3.85%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-3.85%

5 Days

-8.70%

1 Month

+8.70%

6 Months

+224.07%

Year to Date

+88.51%

1 Year

+29.31%

View Detailed Chart

TradingKey Stock Score of 4D Molecular Therapeutics Inc

Currency: USD Updated: 2025-11-07

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

4D Molecular Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

67 / 407

Overall Ranking

183 / 4614

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 10 analysts

Buy

Current Rating

30.714

Target Price

+192.52%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

4D Molecular Therapeutics Inc Highlights

StrengthsRisks

4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia. In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease.

Growing

The company is in a growing phase, with the latest annual income totaling USD 37.00K.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 37.00K.

Fairly Valued

The company’s latest PE is -2.97, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 40.60M shares, decreasing 30.22% quarter-over-quarter.

Held by PRFDX

Star Investor PRFDX holds 27.93K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 1.89.